Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal
Odds, F.C.
Current Opinion in Investigational Drugs 7(8): 766-772
2006
ISSN/ISBN: 1472-4472 PMID: 16955689 Document Number: 595334
Basilea Pharmaceutica is developing BAL-8557, a water-soluble prodrug of the triazole BAL-4815, for the potential treatment of fungal infections. By August 2005, a phase II study in oral candidiasis was underway. In September 2005, phase III trials were planned for invasive Candida and mold infections, including aspergillus and zygomycetes.